Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics is supported by a favorable regulatory and reimbursement setup for OLC, with approval now assumed in late 2026 and TDAPA designation expected in mid 2027, potentially making it the only phosphate binder paid outside the ESRD bundle through mid-2029. The company’s downside from the June 2025 and June 2026 CRLs appears limited because the FDA raised no efficacy or safety concerns and requested no additional data, while the new vendor has a clean March 2024 “No Action Indicated” inspection record and completed 12-month stability studies. Although peak OLC sales and commercialization ramp were trimmed and R&D and SGA estimates were adjusted upward, the combination of a large dialysis market, reimbursement protection, and a cleaner manufacturing path underpins the positive outlook.

Unicycive Therapeutics is a clinical-stage biotech with no product revenue and a history of operating losses, so its value remains dependent on a successful OLC approval and commercialization that has already been delayed by FDA manufacturing inspection issues and a prior Complete Response Letter. The company’s $61.4M in cash and securities provides runway into 2027, but it may still need additional capital to fund launch infrastructure and salesforce deployment, raising dilution risk amid a limited balance sheet and no ATM issuance in 3Q to date. Its outlook is further pressured by uncertain uptake in hyperphosphatemia, reimbursement complexity under ESRD PPS and TDAPA, and direct competition from generic sevelamer, Fosrenol, and other approved binders that could limit pricing power and market penetration.